Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2010

View Archived Issues

New selective ligands of GABA(A) alpha5 receptor claimed

Enrollment complete in phase III trial of subcutaneous Herceptin in HER2+ breast cancer

Topaz Pharma completes phase III trials of topical ivermectin for head lice

Development of cancer stem cell-targeting agents SL-401 and SL-501 continues

Phase I data presented on volociximab/ranibizumab combination in wet AMD

First-in-human trial supports benefits of BKT-140 in autologous transplantation for multiple myeloma

CUDC-101 shows good tolerability in first-in-human trial in advanced solid tumors

Preclinical data presented on antitumor candidates 4SC-202 and 4SC-207

Radient Pharma and Jaiva Technologies form NuVax Therapeutics

Geron obtains license to Angiochem's peptide technology and ANG-1005

European approval of Brilique for prevention of atherothrombotic events

Alexza provides regulatory update for Staccato Loxapine

BELLUS Health presents new amino acid derivatives as analgesics

NRC claims new neuraminidase inhibitors

Cephalon and Mesoblast join to develop mesenchymal precursor stem cell therapies

New TRPV1 channel ligands disclosed

Ascenta and LLS collaborate to develop AT-406

Dynavax reports data from phase Ia trial of universal flu vaccine component

FDA advisory committee makes recommendation on vandetanib NDA

Alkermes presents phase II data on ALKS-33 in alcohol dependence

Galapagos completes first-in-human study of GLPG-0492 in cachexia

FDA committee recommends approval of obesity treatment Contrave

Baylor Research Institute and Roche partner for immunology research

Polyphor divulges new chemokine CXCR4 receptor antagonists

FDA orphan drug status for QLT-091001 in retinitis pigmentosa and LCA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...